Celsus aims to capitalize on its proprietary drug platform by advancing unique drug candidates from the pre-clinical stages to clinical development and thus generating safety and efficacy data while de-risking the drug development program. For each program (e.g. rhinitis, dermatology, etc) Celsus aims to find an appropriate licensing partner (i.e. a pharmaceutical company). The timing and value of the licensing deal will vary for each indication but as more and more compounds are licensed off, new ones from our pipeline are brought forward and the threshold required for licensing is reduced while the returns increase.
To contact investor relations at Celsus Therapeutics Plc, please email firstname.lastname@example.org or call 1-646-350-0702.